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Neural hyperactivity in the amygdala 
induced by chronic treatment of rats 
with analgesics may elucidate the mechanisms 
underlying psychiatric comorbidities associated 
with medication-overuse headache
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Abstract 
Background: Patients with medication-overuse headache suffer not only from chronic headache, but often from 
psychiatric comorbidities, such as anxiety and depression. The mechanisms underlying these comorbidities are 
unclear, but the amygdala is likely to be involved in their pathogenesis. To investigate the mechanisms underlying 
the comorbidities we used elevated plus maze and open field tests to assess anxiety-like behavior in rats chronically 
treated with analgesics. We measured the electrical properties of neurons in the amygdala, and examined the cortical 
spreading depression (CSD)-evoked expression of Fos in the trigeminal nucleus caudalis (TNC) and amygdala of rats 
chronically treated with analgesics. CSD, an analog of aura, evokes Fos expression in the TNC of rodents suggesting 
trigeminal nociception, considered to be a model of migraine.
Results: Increased anxiety-like behavior was seen both in elevated plus maze and open field tests in a model of 
medication overuse produced in male rats by chronic treatment with aspirin or acetaminophen. The time spent in 
the open arms of the maze by aspirin- or acetaminophen-treated rats (53 ± 36.1 and 37 ± 29.5 s, respectively) was 
significantly shorter than that spent by saline-treated vehicle control rats (138 ± 22.6 s, P < 0.001). Chronic treatment 
with the analgesics increased the excitability of neurons in the central nucleus of the amygdala as indicated by their 
more negative threshold for action potential generation (–54.6 ± 5.01 mV for aspirin-treated, –55.2 ± 0.97 mV for 
acetaminophen-treated, and –31.50 ± 5.34 mV for saline-treated rats, P < 0.001). Chronic treatment with analgesics 
increased the CSD-evoked expression of Fos in the TNC and amygdala [18 ± 10.2 Fos-immunoreactive (IR) neurons 
per slide in the amygdala of rats treated with aspirin, 11 ± 5.4 IR neurons per slide in rats treated with acetaminophen, 
and 4 ± 3.7 IR neurons per slide in saline-treated control rats, P < 0.001].
Conclusions: Chronic treatment with analgesics can increase the excitability of neurons in the amygdala, which 
could underlie the anxiety seen in patients with medication-overuse headache.
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Background
Medication-overuse headache (MOH) is defined by the 
International Headache Society as chronic headache 
that occurs 15 or more days a month induced as a con-
sequence of medication for acute or symptomatic head-
ache for more than 3 months. This clinical syndrome is 
common. Population-based studies found the prevalence 
of MOH to be from 0.7 to 1.7%, with higher preponder-
ance in women (74%) than in men (26%) [1]. MOH is 
believed to be an interaction between the medication 
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used excessively and susceptible patients, mainly those 
with migraine or tension-type headache (or both). A 
study in an interdisciplinary pain clinic showed that the 
odds ratio for a patient with medication overuse to have 
chronic headache if they had a history of primary head-
ache, compared with patients without a primary head-
ache syndrome, was 13.1 [2].
Patients with MOH suffer not only from chronic 
headache, but often also from comorbid psychiatric 
symptoms. Compared with patients who have episodic 
migraine and controls without headache, patients with 
MOH showed a greater risk of depressive, obsessive–
compulsive, generalized anxiety, and panic disorders [3, 
4]. Patients with MOH also tended to be more susceptible 
to dependency on the overused medications, resembling 
substance abuse [4]. The cause-and-effect relationship 
between chronic headache and these psychiatric comor-
bidities is controversial. These psychiatric manifestations 
may be viewed as a consequence of chronic pain, because 
coexisting depression and anxiety are common in pain 
syndromes other than headache. Alternatively, the psy-
chiatric comorbidities and headache may be the result of 
a common trigger, being chronic exposure to the acute 
medication.
Previously, our group has shown that chronic treat-
ment with analgesics can increase cortical excitability 
and facilitate trigeminal nociception in animal models 
of headache [5, 6]. We also showed that these changes 
resembled those observed in rats with decreased seroto-
nin (5-hydroxytrptamine; 5-HT) levels [7, 8]. Relatively 
low levels of 5-HT have been found in the platelets of 
patients with MOH compared with controls without 
headache [9]. It is therefore possible that cortical hyper-
excitability and nociceptive facilitation may be the result 
of a derangement of the endogenous 5-HT-dependent 
pain control system. An alteration in this control system 
could also alter the function of subcortical structures 
governing the affective system.
The present study was conducted to investigate 
whether chronic treatment with analgesics can alter 
subcortical structures involved in the control of anxi-
ety. We compared the effect of chronic treatment with 
aspirin and acetaminophen, analgesics commonly used 
by patients with chronic headache. To avoid the known 
effect of sex hormone interaction with chronic analgesic 
drug treatment, we used a model of medication-overuse 
produced in male rats. To investigate the mechanisms 
underlying the comorbidity of anxiety associated with 
medication overuse we assessed anxiety-like behavior 
in chronically treated rats using elevated plus maze and 
open field tests. We compared the electrical properties of 
neurons in central nucleus of the right amygdala, a struc-
ture that may play important role in the pathogenesis of 
depression and anxiety, in rats chronically treated with 
analgesics, and saline-treated vehicle control rats. To 
investigate the mechanisms underlying headache and the 
psychiatric comorbidities, we examined the expression of 
Fos in the trigeminal nucleus caudalis (TNC) at level of 
C1 and C2 in the spinal cord level and in the amygdala 
evoked by cortical spreading depression (CSD), an analog 
of the aura that precedes migraine.
Methods
Animals
Adult male Wistar rats weighing 200–250  g were pur-
chased from the National Laboratory Animal Center, 
Mahidol University, Nakhon Pathom, Thailand. Rats were 
housed in stainless-steel cages in a ventilated room under 
a 12-h dark–light cycle, and were allowed free access to 
food and water. All of the protocols used in this study 
were approved by the Animal Care and Use Committee, 
Faculty of Medicine, Chulalongkorn University, Bangkok, 
Thailand (CU-ACUC No. 16/57).
Drugs and treatments
Aspirin (A2093) was purchased from Sigma-Aldrich. 
Aspirin does not usually dissolve fully in normal saline. 
We carefully added NaH2CO3 to an aspirin-in-saline 
solution, while monitoring the pH until it reached 7.0, 
and presented as a clear solution. The aspirin solution 
was freshly prepared before use. The dose of aspirin used 
in the present experiments was 100  mg/kg body weight 
according to its antinociceptive effect [10]. Acetami-
nophen (paracetamol) was purchased from T.P. Drug 
Laboratories (Bangkok, Thailand). Each ampoule con-
tained 300 mg/2 mL. The dose of acetaminophen used in 
the present experiments was 200 mg/kg [6–8, 11]. Nor-
mal saline was administered to rats in the vehicle control 
group. The volume of all drug injections was calculated 
according to standard criteria (intraperitoneally 10  mL/
kg) [12]. Doses of analgesics were chosen based on the 
presence of efficacy without serious adverse effects [6–8, 
10, 11]. Intraperitoneal injections of the calculated dose 
or vehicle control were made daily from 8:00 to 9:00 am.
Study design
The present study included two experiments. The first 
experiment aimed to determine the effect of chronic anal-
gesic treatment on anxiety-like behavior and the electrical 
activity of neurons in the amygdala. Using computer-gen-
erated random table, rats were divided into three groups 
(10 rats each) receiving aspirin, acetaminophen, or nor-
mal saline. The number of rats in each group was guided 
by our previous study [6–8]. Aspirin (100 mg/kg), aceta-
minophen (200 mg/kg), or normal saline vehicle (10 mL/
kg) was administered intraperitoneally once daily for 
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30 days. Twenty-four hours after the final dose, anxiety-
like behavior was measured using elevated plus maze and 
open field tests. After measuring behavior, the rats were 
humanely killed, their brains removed, and slices pre-
pared for electrophysiological measurement of neurons 
in the amygdala (two brain slices per rat).
The second experiment aimed to investigate the effect 
of chronic analgesics treatment on activation of amygdala 
neurons evoked by CSD that induced trigeminal nocicep-
tion. In this experiment, studied analgesics were admin-
istered as they were in the first experiment (10 rats per 
group). Twenty-four hours after the final dose, rats were 
prepared for activation of CSD using crystalline granules 
of KCl (3  mg). Cortical activity was monitored for 1  h. 
After completion, rat brains were removed and prepared 
for Fos immunohistology. We compared the expression 
of Fos in the TNC and amygdala of rats from the three 
groups.
To exclude the influence of hepatotoxicity possibly 
induced by medication, the rat livers were removed for 
histopathological examination. Hepatotoxicity indicators 
used in present study were presence of centrilobular or 
panacinar necrosis and sinusoidal congestion. All obser-
vations were made by investigators who were blinded to 
the rat treatments.
Experiment 1
The effect of chronic treatment with analgesics on anxi-
ety-like behavior and electrical activity of neurons in the 
amygdala.
Measurement of anxiety‑like behavior—elevated 
plus maze test
Twenty-four hours after the final dose of drug admin-
istration, anxiety-like behavior was measured using an 
elevated plus maze according to a standard method 
described by Pellow et  al. [13]. Briefly, an elevated plus 
maze consisted of four arms connected by a central 
square (10 cm × 10 cm). Two of which were open arms 
(50 cm × 10 cm) and the other two were enclosed arms 
(50 cm × 10 cm × 40 cm) with same type of arm oppo-
site to each other. The apparatus was elevated 50  cm 
above the floor. The arms were connected by a central 
10 cm × 10 cm2. Each rat was placed in the center square 
of the maze facing an open arm and allowed to explore 
freely for 5 min. The rat was considered to have entered 
an arm when all 4 limbs were inside the arm. 70% etha-
nol solution was used to clean the apparatus after each 
trial. (1) Time spent in open arms; (2) number of open 
arm entries; (3) time spent in closed arms; (4) number of 
closed arm entries; (5) time spent on the center platform; 
and (6) number of center platform crossings are recorded 
during the 5 min test period. All behavior variables were 
scored by an investigator who was blinded to the rat 
treatments.
Measurement of anxiety‑like behavior—open field test
Black plastic box (76  cm long  ×  57  cm wide  ×  50  cm 
high) with a 48-square grid floor (8 × 6 squares, 9.5 cm 
per side) was used in open field test (as modified from 
Rex et al. [14]). After the elevated plus maze test session, 
the open field test was conducted by placing the rat in 
center of the open field. The field arena was divided into 3 
parts (outer, 8 × 6 squares next to the wall; middle, 6 × 4 
squares next to the outer area; and inner, 4 × 2 squares 
in the center area). The rat was allowed to explore the 
arena for 5 min. Time spent in each part represented the 
anxiety-like behavior. The number of total crosses the rat 
made during 5 min session was recorded as its locomo-
tor activity. The experiments were recorded by a digital 
video camera recorder for later analysis. After each trial, 
the plate was cleaned with a 70% ethanol solution. All 
behavioral variables were scored by an investigator who 
was blinded to the rat treatments.
Preparation of the amygdala slices
One day after behavioral measurements, rats were decap-
itated under isoflurane anesthesia (Fisher Scientific, 
Hanover Park, IL). Their brains were harvested and sub-
merged in ice cold modified Ringer’s solution contain-
ing 234  mM sucrose, 2.5  mM KCl, 1.25  mM NaH2PO4, 
10  mM MgSO4, 0.5  mM CaCl2, 26  mM NaHCO3, and 
11  mM glucose, and was sparged with 95% O2/5% 
CO2, pH 7.4 for 2–3 min. Coronal slices (about 300 μm 
thick) of the right amygdala (approximately –1.46  mm 
to bregma) were cut using a microtome (Vibratome 
1500, Vibratome, Bannockburn, IL) and incubated in 
standard Ringer’s solution (125 mM NaCl, 2.5 mM KCl, 
2 mM CaCl2, 1 mM MgCl2, 26 mM NaHCO3, 1.25 mM 
NaH2PO4, and 25 mM Glucose sparged with 95% O2/5% 
CO2, pH 7.4) at room temperature for 1 h before record-
ing. After incubation, recorded slices were placed indi-
vidually in a recording chamber on the stage of an 
upright microscope (BX51W1; Olympus, Tokyo, Japan) 
and were continuously superfused with standard Ringer’s 
solution with flow rate of 3–5 mL/min using a peristaltic 
pump (Minipuls 3, Gilson, Villiers, France).
Brain slice neuronal recording
Whole-cell patch-clamp recordings were made of neu-
rons in slices of the lateral subdivision of the central 
nucleus of the right amygdala (CeL) under visual control 
using patch pipettes connected to a patch-clamp ampli-
fier (Axopatch 200B, Axon Instruments, Foster City, CA). 
The patch pipettes were pulled from borosilicate glass 
capillaries (B150-86-10, 1.5 mm outside diameter, Sutter 
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Instruments, Novato, CA) using a horizontal electrode 
puller (P-97; Sutter Instruments). The pipettes were filled 
with a solution containing: 140 mM K-gluconate, 20 mM 
KCl, 0.2  mM ethylene glycol tetraacetic acid, 2  mM 
MgCl2, 2 mM Na2ATP, 0.5 mM Na3GTP, 10 mM HEPES, 
and 0.1 mM spermine (pH 7.4). –10 mV liquid junction 
potential between the Ringer’s solution and the gluco-
nate-based intrapipette solution was estimated. There-
fore, the actual membrane potential was corrected by this 
value. The intrapipette solution was 280–290  mOsm/L. 
The electrodes resistance was 5–8 MΩ in bath solutions. 
All recordings were performed at 32–34 °C. One to three 
neurons were recorded per slice. Data were acquired 
through a low-pass filter at 3 kHz (8-pole Bessel filter) at 
a sampling rate of 10 kHz. Stimulus generation and data 
acquisition were performed using a pClamp 10.2 oper-
ated via a Digidata 1440A interface board (Axon Instru-
ments) on a personal computer. Data were analyzed later 
using Clampfit software (Axon Instruments).
Experiment 2
The effect of chronic treatment with analgesics on acti-
vation of amygdala neurons evoked by CSD that induced 
trigeminal nociception.
Extracellular cortical activity recording and CSD induction
One day after the final dose of analgesic administration, 
rats were anesthetized with an intraperitoneal injec-
tion of sodium pentobarbital (60  mg/kg). Their heads 
were fixed to the head holder of a stereotaxic frame. For 
direct current (DC) recordings, a small window on the 
skull (2 mm in diameter) was created in the right frontal 
bone (3 mm anterior to the bregma and 2 mm lateral to 
the midline). Dura mater was then carefully removed and 
a glass microelectrode for detecting negative DC poten-
tial was inserted into the frontal cortex using a hydraulic 
micromanipulator (Narishige, Tokyo, Japan) to a depth of 
500 μm. An Ag/AgCl reference electrode was placed on 
the skin on the back of the rat. A parietal window (7 mm 
posterior and 3 mm lateral to the bregma) was prepared 
to elicit CSD by application of crystalline granules of KCl 
(3 mg) onto intact dura mater overlying parietal cortex. 
The granules were washed away with synthetic intersti-
tial fluid at the end of the CSD wave at approximately 
1  h (method modified from Leão [15]). The DC electri-
cal signal was amplified using a microelectrode amplifier 
(Nihon Kohden, Tokyo, Japan). An MP100 data acquisi-
tion system (Biopac Systems, Goleta, CA) was used to 
convert analog data into digital format which were then 
analyzed using AcqKnowledge acquisition software 
(Biopac Systems). The number of CSD waves occurred 
within 60 min was determined.
Fos immunohistochemistry
Two hours after KCl was applied onto the intact dura 
mater overlying the parietal cortex, rats were deeply 
anesthetized with sodium pentobarbital overdose. After 
that they were transcardially perfused with 0.1 M phos-
phate buffer pH 7.4 (PBS), followed by 4% paraformal-
dehyde in 0.1 M PBS, pH 7.4. The brain and spinal cord 
were cut into a block containing C1 and C2 of the spi-
nal cord, and amygdala areas. After immersion in 30% 
sucrose until saturated for cryoprotection, the block was 
sectioned coronally on a cryostat and 30 μm thick slices 
were collected into cold PBS. Serial sections were col-
lected from brains of rats from the three groups for Fos 
immunohistology using a free-floating technique. After 
pretreatment with 1% H2O2 in PBS for 30 min for endog-
enous peroxidase activity quenching and 3% normal goat 
serum in PBS for 1 h for nonspecific binding sites block-
ing, sections were then incubated with rabbit anti-Fos 
polyclonal antibody (sc-52 lot No. A-1915; Santa Cruz 
Biotechnology, Dallas, TX) at 1:1000 for 24  h at 4  °C. 
After incubation, biotinylated secondary goat anti-rab-
bit IgG (BA-1000; Vector Laboratories, CA, USA) was 
applied to sections to detect the primary. The sections 
were then incubated with avidin DH: biotinylated horse-
radish peroxidase H complex (ABC kit; Vector Laborato-
ries, CA). The Fos immunoreactivity was visualized using 
peroxidase reaction by incubating the sections in 0.03% 
3,3′-diaminobenzidine tetrahydrochloride and 0.008% 
H2O2 in 0.05 M Tris–HCl for 8–10 min. Finally, the sec-
tions were mounted on glass slides, dehydrated in etha-
nol, cleared in xylene, air dried, and coverslipped. Five 
Fos-stained sections per C1–C2 or amygdala level per 
rat were chosen for counting cells. Fos-immunoreactive 
(IR) cells in Rexed laminae I and II were counted and 
expressed as number of cells per section. The cell count-
ing was conducted by an investigator who was blinded to 
rat treatments.
Statistical analyses
Data were analyzed using PASW Statistics for Windows 
(version 18; SPSS Inc, Chicago, IL). All variables are 
expressed as mean ±  SD. Differences between the vari-
ous groups were tested using a one-way analysis of vari-
ance (ANOVA) followed by a Dunnett test. All analyses 
used a two-tailed hypothesis testing method. P  <  0.05 
was considered to be significant.
Results
Chronic aspirin and acetaminophen treatment did not 
alter general rat behavior, including feeding. The aver-
age body weights of rats on the day of behavioral test-
ing were comparable between the groups (317 ±  14.7 g 
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for aspirin-treated rats, 309 ± 7.5 g for acetaminophen-
treated rats, and 316  ±  5.4  g for saline-treated control 
rats). Liver toxicity was excluded by histology, which 
demonstrated no hepatocellular necrosis.
Effect of chronic treatment with analgesics on anxiety‑like 
behavior
Chronic treatment with analgesics increased anxiety-
like behavior in the elevated plus maze without affecting 
the locomotor function seen in the open field test. In the 
elevated plus maze test, the number of entries into open 
arms and time spent in the open arms were lower in aspi-
rin- or acetaminophen-treated rats than those for saline-
treated control rats, whilst the time spent in the closed 
arm was increased after treatment with either analge-
sic. Aspirin-treated rats spent 53  ±  36.1  s in the open 
arms, acetaminophen-treated rats spent 37 ± 29.5 s, and 
saline-treated rats spent 137  ±  22.6  s (P  <  0.001; F2,27 
32.8; Fig.  1a; Additional file  1: Table  S1). There was no 
significant difference in any variable between aspirin-
treated or acetaminophen-treated rats. No significant 
difference was detected in the amount of central crossing 
by rats from any of the three groups. Aspirin-treated rats 
spent 62 ± 23.8 s in central area, acetaminophen-treated 
rats spent 49  ±  31.0  s, and saline-treated rats spent 
52 ± 22.1 s (P = 0.48; F2,27 0.75; Fig. 1b).
Consistent with the elevated plus maze results, the 
open field test also indicated an increase in anxiety-like 
behavior by rats chronically treated with an analgesic. 
Rats chronically treated with either aspirin or acetami-
nophen tended to stay on the periphery of the field with-
out entering the center. The time spent in outer areas by 
rats chronically treated with either analgesic was signifi-
cantly greater than time spent by rats treated with saline 
(240  ±  28.4  s for aspirin-treated rats, 221  ±  34.4  s for 
acetaminophen-treated rats, and 145 ± 19.0 s for saline-
treated control rats; P  <  0.001; F2,27 32.02; Fig.  1c). The 
numbers of total crosses by rats in the three groups 
were comparable (132  ±  51.3  s for aspirin-treated 
rats, 131  ±  26.5 for acetaminophen-treated rats, and 
133  ±  10.4  s for saline-treated rats, P  =  0.997; F2,27 
0.003; Fig. 1c). There was no significant difference in the 
number of crosses by rats treated with either analgesic 
(Fig. 1c).
Effect of chronic treatment with analgesics on electrical 
properties of neurons in the amygdala
A total of 30 neurons (10 neurons per group) were 
selected from the lateral subdivision of the central 
nucleus of the right amygdala (CeL). All selected neurons 
Fig. 1 The effect of chronic treatment of rats with analgesics on the 
duration (a) and number of open-arm entries (b) on an elevated plus 
maze, and open field test results (c) (mean ± SD for 10 rats). *P < 0.05 
compared with normal saline-treated control rats, one-way ANOVA 
followed by a Dunnett test
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had to meet stringent criteria for health and stability. 
These healthy neurons had an input resistance between 
180 and 220  MΩ and access resistance <16  MΩ. The 
holding potential of each neuron was –70  mV. Incre-
mentally increasing current was injected as brief (1 ms) 
current pulses in a ladder of 10 pA steps until an action 
potential was generated. The threshold was considered 
as the first step generating an action potential. Chronic 
treatment of rats with analgesics increased the excit-
ability of the neurons in their CeL (Fig.  2). The thresh-
olds for action potential generation in neurons from 
aspirin-treated (–54.6 ±  5.01  mV) and acetaminophen-
treated (–55.2  ±  0.97  mV) rats were more negative 
than for neurons from saline-treated vehicle control 
rats (–31.5 ±  5.34  mV). P  <  0.001; F2,27 99.67. Neurons 
in the CeL from rats chronically treated with analgesics 
depolarized faster than those from saline-treated con-
trol rats. The ratio of signal amplitude and rapid depo-
larization time was greater in rats chronically treated 
with analgesics (97.2 ±  11.69  mV/ms for neurons from 
aspirin-treated rats, 107.5  ±  10.87  mV/ms for neurons 
from acetaminophen-treated rats, and 66.5 ±  5.54  mV/
ms for neurons from saline-treated rats. P < 0.001; F2,27 
47.85). There was no significant difference in the rest-
ing membrane potential of the neurons from rats in 
the three groups. The resting membrane potential was 
–64.2 ±  6.44  mV for neurons from aspirin-treated rats, 
–62.0  ±  5.53  mV for neurons from acetaminophen-
treated rats, and –64.0  ±  2.70  mV for neurons from 
saline-treated rats, (P = 0.58, F2,27 = 0.56).
Effect of chronic treatment with analgesics on CSD 
generation
Chronic treatment with aspirin or acetaminophen 
altered the pattern of CSD generation (Fig.  3; Addi-
tional file  1: Table  S2). This effect was more prominent 
in acetaminophen-treated rats (n =  10 per group). The 
CSD depolarization waves in rats chronically treated with 
acetaminophen were more frequent and had diminished 
duration, area-under-the curve, and interpeak latency. 
The presence of small, poorly developed CSD waves was 
observed in rats treated with either analgesic (Fig. 3). The 
average number of CSD waves developed in the first hour 
was 6 ±  0.4 in aspirin-treated rats, 8 ±  1.3 in acetami-
nophen-treated rats, and 5 ± 0.3 in saline-treated control 
rats (P < 0.001; F2,27 39.43; Fig. 3). A similar CSD pattern 
was observed between acetaminophen- and aspirin-
treated rats, but the area-under-curve was significantly 
smaller in acetaminophen-treated rats (Fig. 3).
Effect of chronic treatment with analgesics on CSD‑evoked 
Fos expression
Chronic treatment with analgesics significantly increased 
CSD-evoked Fos expression in both sides of the TNC 
with greater prominence on the side ipsilateral (right) to 
the CSD stimulus (Fig. 4; Additional file 1: Table S3). In 
the ipsilateral (right) TNC of aspirin-treated rats there 
were 27  ±  9.6 Fos-IR neurons per slide, 20  ±  5.4 neu-
rons per slide in acetaminophen-treated rats, and 6 ± 2.2 
neurons per slide in saline-treated control rats (P < 0.001; 
F2,27 27.81). Only the contralateral (left) side of the TNC 
of aspirin-treated rats had significantly (P = 0.04) more 
Fos-IR cells than acetaminophen-treated rats.
Chronic treatment with analgesics increased Fos 
expression in both the ipsilateral (right) and contralat-
eral (left) amygdala (Fig.  5; Additional file  1: Table  S3). 
Fos-IR neurons were confined to the capsular region of 
the central amygdala. In the ipsilateral (right) amygdala 
there were 18  ±  10.2 Fos-IR neurons per slide in aspi-
rin-treated rats, 11 ±  5.4 neurons per slide in acetami-
nophen-treated rats, and 4  ±  3.7 neurons per slide in 
saline-treated control rats, P < 0.001; F2,27 10.04). Unlike 
the TNC, a greater degree of change was observed in 
the contralateral (left) amygdala. In the contralateral 
(left) amygdala there were 24 ± 17.2 Fos-IR neurons per 
slide in aspirin-treated rats, 21 ±  9.9 neurons per slide 
in acetaminophen-treated rats, and 3 ± 2.3 neurons per 
slide in saline-treated control rats (P < 0.001; F2,27 8.65). 
There was no significant difference in the numbers of 
Fos-IR neurons between amygdala from aspirin- or 
acetaminophen-treated rats.
Discussion
Chronic treatment with the analgesics induced signifi-
cant changes in the system that controls emotion includ-
ing anxiety. Animals receiving chronic treatment with the 
analgesics showed anxiety-like behavior and increased 
activity in the neurons of amygdala. Chronic treatment 
with analgesics also enhanced the development of CSD 
and facilitated the activity of neurons in the trigeminal 
nociceptive pathway and in the central nucleus of the 
amygdala.
(See figure on next page.) 
Fig. 2 Representative traces of action potentials from neurons in the lateral central nucleus of the right amygdala (CeL) from rats chronically treated 
with the analgesics, and from saline-treated control rats. a Control, b acetaminophen, and c aspirin. The location of recorded neurons is shown in the 
inset. The bar graph compares the resting membrane potential, action-potential threshold, and ratio of rapid depolarization time and signal ampli-
tude (mean ± SD of 10 animals). The threshold for action-potential generation in CeL neurons from rats chronically treated with aspirin or acetami-
nophen was more negative than that in control neurons from saline-treated rats. *P < 0.05, one-way ANOVA followed by a Dunnett test
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Anxiety is common in patients with chronic head-
ache associated with analgesic overuse. This association 
may be causally related, either chronic headache causing 
anxiety or the converse. In this paradigm, an index dis-
order causes or predisposes individuals to developing the 
comorbid disorder [16]. Therefore, this association must 
be unidirectional in nature [16]. However, epidemiologi-
cal and clinical evidence suggests that the association 
between chronic headache and psychiatric disorders is 
bidirectional. Psychiatric disorders are found to be sig-
nificant risk factors for development of MOH [16], and 
coexisting psychiatric disorders predict a worse outcome 
of MOH treatment [17, 18]. This bidirectional associa-
tion implies that both MOH and anxiety are the result 
of chronic analgesic exposure. The presence of anxiety-
like behavior in rats chronically treated with analgesics is 
consistent with this bidirectional association hypothesis.
In the present study, we demonstrated that neurons of 
the central amygdala nucleus of rats chronically treated 
with analgesics have a decreased action potential thresh-
old. The amygdala plays an important role in fear and 
anxiety [19]. Each amygdala can be subdivided into three 
major nuclei, namely the lateral nucleus, basolateral 
complex, and central nucleus [19]. The lateral nucleus 
receives multimodal sensory information from the thala-
mus and cortex, and projects to the central amygdala via 
the basolateral complex. The central amygdala serves as a 
major output station. Neurons in the central nucleus send 
outputs to several brainstem and hypothalamic nuclei 
involved in the generation of conditioned fear responses 
[19]. Bilateral destruction of the central amygdala results 
in a decrease of fear-related behavior and decreased lev-
els of corticotrophin-releasing factor in the cerebrospi-
nal fluid and decreased levels of adrenocorticotropic 
hormone in the plasma [20]. Bilateral lesions of central 
amygdala also prevent visceral (bladder) hyperalgesia, 
which was induced by acute stress (foot shock) [21]. By 
contrast, increased activity of neurons in the central 
amygdala has been observed in models of chronic pain. 
For instance, neurons in the central amygdala of arthritic 
rats developed increased excitability compared with 
vehicle- or untreated controls [22]. A decreased action 
potential threshold of neurons in the central amygdala in 
rats chronically treated with analgesics as shown in the 
present study suggests that the activity of this nucleus is 
facilitated after prolonged exposure to analgesics. This 
facilitation may underlie the development of anxiety seen 
in patients with MOH.
We showed that in addition to evoking Fos expres-
sion seen as immunoreactivity in the TNC, CSD also 
evoked Fos expression in the capsular region of central 
amygdala. This region has been defined as the “nocic-
eptive amygdala” because it relays nociceptive specific 
information from the spinal cord and brainstem via 
spino-(trigemino-)parabrachio-amygdaloid pathway 
[23]. Neurons in this region of the central amygdala may 
Fig. 3 Representative cortical spreading depression DC potential response to KCl applied onto the dura mater of rats chronically treated with 
acetaminophen or aspirin, and saline-treated control rats. The lower panel compares variables including peak amplitude, duration, latency, and num-
ber, and area under the curve. *P < 0.05 compared with the CSD response in saline-treated control rats, one-way ANOVA followed by a Dunnett test
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Fig. 4 Cortical spreading depression-evoked Fos-immunoreactive neurons in the trigeminal nucleus caudalis of rats chronically treated with 
acetaminophen or aspirin, and normal saline-treated control rats (scale bar 100 μm). The graph presents a statistical analysis of Fos-immunoreactive 
neurons (mean ± SD of counts per slide from 10 rats). *P < 0.05 compared with saline-treated control rats, one-way ANOVA followed by a Dunnett 
test. †P < 0.05 between aspirin and acetaminophen treated rats, one-way ANOVA followed by a Dunnett test
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preferentially respond to noxious stimuli. Interestingly, 
the activity of neurons in this region can be modified 
by calcitonin gene-related peptide (CGRP) that has an 
important part in migraine pathogenesis [24]. Applica-
tion of CGRP receptor antagonists inhibits the synaptic 
plasticity of this region in brain slices from arthritic rats. 
These effects on plasticity were accompanied by decrease 
of neuronal excitability and reduction of amplitude, but 
not frequency, of miniature excitatory postsynaptic cur-
rents compared with those obtained from normal con-
trols [24]. The observation of CSD-evoked Fos expression 
in the central amygdala together with expression of Fos in 
the TNC implies the involvement of the capsular region 
of the central amygdala in trigeminal nociception. We 
note that application of KCl to the dura mater can also 
directly activate dural nociceptive fibers. Therefore, Fos 
can be expressed in the TNC as a result of either process.
We showed that chronic treatment with aspirin or 
acetaminophen had similar, but not identical, effects on 
excitability of neurons. Acetaminophen increased the 
excitability of cortical neurons more strongly than aspi-
rin, while aspirin induced greater expression of Fos in 
the TNC and amygdala. That chronic treatment with 
aspirin increased the level of anxiety-like behavior with-
out altering CSD suggests that there is no direct causal 
relationship between CSD and anxiety. These differ-
ences in the effects of aspirin are consistent with clinical 
observations that although several classes of medication 
can induce chronic headache, the features of MOH fol-
lowing different acute headache medications overuse are 
not exactly the same. A daily tension-type headache usu-
ally develops in patients overusing ergots and analgesics, 
while those overusing triptans were more likely to have 
frequent migraine-like headaches [25]. Unfortunately, to 
our knowledge there are no currently available data for 
the effect of different drugs in inducing psychiatric symp-
toms in patients with MOH.
Conclusions
Chronic exposure to analgesics can increase the excit-
ability of neurons in the central nucleus of the amygdala, 
which may underlie the development of anxiety or depres-
sion seen in patients with MOH. Our findings suggest that 
psychiatric symptoms coexisting with MOH should be 
considered as an epiphenomenon related to medication 
overuse and are not a direct consequence of chronic pain.
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Fig. 5 Cortical spreading depression-evoked Fos-immunoreactive neurons in the central nucleus of the amygdala from rats chronically treated 
with acetaminophen or aspirin, and from saline-treated control rats (scale bar 250 μm in each section and 50 μm in the inset). a Ipsilateral control, 
b ipsilateral chronic acetaminophen, c ipsilateral chronic aspirin, d contralateral control, e contralateral chronic acetaminophen and f contralateral 
chronic aspirin. The graph presents a statistical analysis of Fos-immunoreactive neurons (mean ± SD of counts per slide from 10 rats). *P < 0.05 
compared with neurons in the amygdala of saline-treated control rats, one-way ANOVA followed by a Dunnett test
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